Australia and New Zealand Cutaneous T-cell Lymphoma Market Report and Forecast 2024-2032

Australia and New Zealand Cutaneous T-cell Lymphoma Market Outlook

The Australia and New Zealand cutaneous T-cell lymphoma market size is expected to grow at a CAGR of 11.3% during the forecast period of 2024-2032, driven by the increasing incidence of the condition across the region, along with surge in research activities to offer personalised solutions.

Australia and New Zealand Cutaneous T-cell Lymphoma Market Overview

Cutaneous T-cell lymphoma is a rare type of blood cancer that occurs in the white cells of the body called T-cells. It is subdivided into two major categories, namely mycosis fungoides and Sezary syndrome. It can cause rash-like redness or scaly patches on the skin. In Australia, blood cancer is one of the most common types of cancer accounting for 12% of  all cancer cases in 2023. Approximately 19,500 people are expected to be diagnosed with the condition. The cutaneous T-cell lymphoma prevalence increases with age (mid-50s  is a median age of disease diagnosis), indicating that the geriatric population is at a higher risk. Males are more susceptible to develop the disease.

The Australia and New Zealand cutaneous T-cell lymphoma market growth is driven by increasing prevalence of using latest and innovative technologies to boost the development of effective treatment solutions. In addition, the surge in merger and acquisition activity to meet the rising demand and provide customized solutions to the patients is fueling the market growth as well.

Increase in Research and Development Activities to Meet the Rising Australia and New Zealand Cutaneous T-cell Lymphoma Market Demand

With advancements in gene therapy and biotechnology, along with a deeper understanding of human physiology, there is a significant emphasis on developing effective and targeted therapies to treat the disease. In December 2023, Innate Pharma SA  presented positive data, supporting the use of lacutamab to treat Sezary Syndrome (a subtype of cutaneous T-cell lymphoma). As per the results of Phase 2 TELLOMAK trial, lacutamab, the first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody was found safe and effective with an overall response rate of 46.4% on the skin.

In September 2023, KT-333 , a treatment for relapsed/refractory cutaneous T-cell lymphoma also gained a fast-track designation from the FDA. The novel treatment is based on degrading the STAT3 protein, which has been historically undruggable for treating the condition.

Rising Adoption of Innovative Alternatives to Drive Australia and New Zealand Cutaneous T-cell Lymphoma Market Size

In December 2023, Soligenix, Inc., a late-stage biopharmaceutical company, described the potential use of HyBryte™ to treat cutaneous T-cell lymphoma (CTCL). HyBryte ™ is a first-in-class photodynamic therapy with synthetic hypericin as a potential photosensitizer that is applied topically on skin lesions. It reaches deep within the skin and also prevents the chances of secondary malignancies (including melanoma), which are commonly associated with frequently administering DNA damaging drugs. When used in treating CTCL, the new treatment option demonstrated effectiveness along with safety and catered to a broad section of patients, including different lesion types, different skin tones and different disease stages.

Key Companies Expanding Their Product Portfolios with Surge in Merger and Acquisition Activity

With the rising convergence of new technologies into drug development, Australia and New Zealand cutaneous T-cell lymphoma market share is likely to grow further in the forecast period. In January 2024, AstraZeneca  announced their plan to acquire Gracell Biotechnologies, a clinical-stage biopharmaceutical company specializing in cell therapies for cancer, in a deal expected to cost around USD 1.2 billion. The acquisition is poised to expand AstraZeneca’s pipeline of cell therapies and manufacture potential new treatment for multiple tumours and autoimmune diseases in coming years.

Australia and New Zealand Cutaneous T-cell Lymphoma Market Segmentation

Market Breakup by Disease Type

• Mycosis Fungoides (MF)

• Sezary Syndrome (SS)

Market Breakup by Treatment Type

• Radiation therapy

• Stem Cell Transplantation

• Topical Chemotherapy

• Chemotherapy

• Immunotherapy

Market Breakup by Disease Stage

• Early-Stage (Limited) CTCL

• Advanced-Stage (Advanced) CTCL

Market Breakup by End User

• Hospitals

• Specialty Clinics

• Ambulatory Surgical Centres

Market Breakup by Country

• Australia

• New Zealand

Australia and New Zealand Cutaneous T-cell Lymphoma Market Regional Analysis

With a robust healthcare infrastructure and surge in research and development activities to expedite drug development process, Australia is poised to lead the Australia and New Zealand cutaneous T-cell lymphoma market share in the forecast period. The rising collaborations between research institutions and prominent healthcare companies are poised to add significant market value to the region.

New Zealand is also predicted to experience significant growth owing to the emphasis on improving healthcare infrastructure and the rising awareness about the importance of providing effective solutions to the rising geriatric population in the region. Medical regulatory authorities like Medsafe are continuously approving new drugs to provide quality care to the patients. Moreover, a surge in foreign investments to leverage academic talent along with easily available resources is a major factor boosting market growth.

Australia and New Zealand Cutaneous T-cell Lymphoma Market: Competitor Landscape

In October 2023, Citius Pharmaceuticals, Inc.  announced the acquisition of TenX Keane to establish Citius Oncology, Inc. focused entirely on developing and commercialising oncology therapies. Citius’s, LYMPHIR, a potential treatment for recurring cutaneous T-cell lymphoma is seeking approval from the regulatory authorities. The drug is estimated to exceed a market value of USD 400 million and emerge as a unique IL-2 receptor targeted therapy for the disease. The market has been witnessing continuous mergers and acquisitions to expand their services and expediate the drug development process.

The key features of the Australia and New Zealand cutaneous T-cell lymphoma market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Mylan N.V. (now part of Viatris)

• Celgene Corporation (now part of Bristol Myers Squibb)

• Takeda Pharmaceutical Company Limited

• Mundipharma International Limited

• Novartis AG

• Kyowa Kirin Co., Ltd.

• Incyte Corporation

• Bristol Myers Squibb

• Eli Lilly and Company

• Genentech, Inc. (a member of the Roche Group)

• Seattle Genetics, Inc.

• Almirall, S.A.

• Eisai Co., Ltd. 

• Karyopharm Therapeutics Inc.

• Leo Pharma A/S

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report